clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Uehara H et al. Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin. 2016 Curr. Eye Res. pmid:26125497
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Alarcón-Millán J et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. 2016 Infect. Genet. Evol. pmid:27355861
Khonche A et al. Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. 2016 Drug Res (Stuttg) pmid:27351245
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Wong AY et al. Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. 2016 JAMA Intern Med pmid:27136661
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Iyer G and Alexander GC Editorialists' reply to Blake. 2016 BMJ pmid:26957321
Blake Z Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. 2016 BMJ pmid:26955978
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Raymond J et al. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. 2016 Scand. J. Gastroenterol. pmid:26784882
Kefeli A et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. 2016 Bosn J Basic Med Sci pmid:26773183
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Di Giulio M et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. 2016 Scand. J. Gastroenterol. pmid:26554617
Djennane-Hadibi F et al. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. 2016 Microb. Drug Resist. pmid:26554340
Xuan SH et al. Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review. 2016 J Glob Antimicrob Resist pmid:27436390
Siddiqui TR et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. 2016 J Pak Med Assoc pmid:27339574
Lee J et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26441216
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055
Li BZ et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. 2015 BMJ pmid:26290044
Haider RB et al. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. 2015 Eur J Gastroenterol Hepatol pmid:26287955
Shallom SJ et al. New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. 2015 J. Clin. Microbiol. pmid:26269619
Zagari RM et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. 2015 Dig Liver Dis pmid:26253555
Dimer F et al. Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. 2015 Pharm. Res. pmid:26113237
Kasai A et al. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. 2015 J. Med. Microbiol. pmid:25934551
Mahmoudi A et al. Microbiological assay for the analysis of certain macrolides in pharmaceutical dosage forms. 2015 Int J Pharm pmid:26112961
Flores-Gonzalez JC et al. [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. 2015 Rev Neurol pmid:26108903
Liou JM et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. 2015 PLoS ONE pmid:25942450
Ferreri AJ et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. 2015 Ann. Oncol. pmid:25935794
Ito A et al. Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. 2015 J. Med. Microbiol. pmid:25934550
Metanat HA et al. Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. 2015 Helicobacter pmid:25752357
Essilfie AT et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. 2015 Thorax pmid:25746630
Bouilhat N et al. High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. 2015 Helicobacter pmid:25735573
Guzman Vinasco L et al. Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. 2015 BMJ Case Rep pmid:25733094
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Boltin D et al. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? 2015 J. Clin. Microbiol. pmid:25428158
Moriya S et al. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells. 2015 Int. J. Oncol. pmid:25422130
Tongtawee T et al. High Prevalence of Helicobacter pylori Resistance to Clarithromycin: a Hospital-Based Cross-Sectional Study in Nakhon Ratchasima Province, Northeast of Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26745073
Kim SE et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. 2015 Korean J. Intern. Med. pmid:26552455
Bang CS and Baik GH Time to learn from the past and prepare for the future in Helicobacter pylori eradication. 2015 Korean J. Intern. Med. pmid:26552453
Alimadadi M et al. Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. 2015 Iran J Kidney Dis pmid:26552348
Karpiński TM et al. Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. 2015 Acta Microbiol Immunol Hung pmid:26551571
Chen KY et al. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. 2015 World J. Gastroenterol. pmid:26420970
Apiwattankul N et al. Infections Caused by Rapidly Growing Mycobacteria spp in Children and Adolescents With Cancer. 2015 J Pediatric Infect Dis Soc pmid:26407409
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Hauser G et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. 2015 Medicine (Baltimore) pmid:25929897